Targeting dexamethasone to macrophages in a porcine endotoxemic model

Critical Care Medicine

Volumn 41, Issue 11, 2013, Pages

  Granfeldt, Asger ^a   Hvas, Christine Lodberg ^a   Graversen, Jonas Heilskov ^b   Christensen, Peter Astrup ^b   Petersen, Mikkel Due ^c   Anton, Gabriela ^b   Svendsen, Pia ^c   Sølling, Christoffer ^a   Etzerodt, Anders ^c   Tønnesen, Else ^a   Moestrup, Søren Kragh ^a,c   Møller, Holger Jon ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Cytoguide ApS   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

CD163; Corticosteroids; Cytokines; Inflammation; Lipopolysaccharide; Macrophage

Indexed keywords

CD163 ANTIBODY; CD163 ANTIGEN; CORTICOTROPIN; DEXAMETHASONE; DRUG ANTIBODY; GLUCOCORTICOID; HYDROCORTISONE; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; PLACEBO; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE RESPONSE; ENDOTOXEMIA; FEMALE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; LABORATORY; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; SWINE; UNIVERSITY HOSPITAL;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; ENDOTOXEMIA; FEMALE; GLUCOCORTICOIDS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGES; RANDOM ALLOCATION; RECEPTORS, CELL SURFACE; SWINE;

EID: 84887075840     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31828a45ef     Document Type: Article

References (32)

1. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353:1711-1723
2. Schäcke H, Döcke WD, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96:23-43
3. Adcock IM, Caramori G, Kirkham PA: Strategies for improving the efficacy and therapeutic ratio of glucocorticoids. Curr Opin Pharmacol 2012; 12:246-251
4. Sprung CL, Goodman S, Weiss YG: Steroid therapy of septic shock. Crit Care Clin 2009; 25:825-834
5. Schumer W: Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184:333-341
6. Cronin L, Cook DJ, Carlet J, et al: Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23:1430-1439
7. Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
8. Gordon S: The macrophage: Past, present and future. Eur J Immunol 2007; 37(Suppl 1):S9-S17
9. Kotsaki A, Giamarellos-Bourboulis EJ: Emerging drugs for the treatment of sepsis. Expert Opin Emerg Drugs 2012; 17:379-391
10. Cavaillon JM, Adib-Conquy M: Monocytes/macrophages and sepsis. Crit Care Med 2005; 33(12 Suppl):S506-S509
11. Ghezzi P, Cerami A: Tumor necrosis factor as a pharmacological target. Mol Biotechnol 2005; 31:239-244
12. Sacre SM, Andreakos E, Taylor P, et al: Molecular therapeutic targets in rheumatoid arthritis. Expert Rev Mol Med 2005; 7:1-20
13. Graversen JH, Svendsen P, Dagnas-Hansen F, et al: Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther 2012; 20:1550-1558
14. Pulford K, Micklem K, McCarthy S, et al: A monocyte/macrophage antigen recognized by the four antibodies GHI/61, Ber-MAC3, Ki-M8 and SM4. Immunology 1992; 75:588-595
15. Moestrup SK, Møller HJ: CD163: A regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004; 36:347-354
16. Van Gorp H, Delputte PL, Nauwynck HJ: Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol 2010; 47:1650-1660
17. Kristiansen M, Graversen JH, Jacobsen C, et al: Identification of the haemoglobin scavenger receptor. Nature 2001; 409:198-201
18. Etzerodt A, Maniecki MB, Graversen JH, et al: Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release 2012; 160:72-80
19. Graversen JH, Svendsen P, Christensen PA, et al: Agents, Uses and Methods. WO/2011/039510
20. Madsen M, Møller HJ, Nielsen MJ, et al: Molecular characterization of the haptoglobin hemoglobin receptor CD163. Ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem 2004; 279:51561-51567
21. Bailey G. The chloramine T method for radiolabeling protein. In: The Protein Protocols Handbook. Walker JM (Ed). Humana Press, 2002, pp 963-965
22. Maniecki MB, Etzerodt A, Moestrup SK, et al: Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression. Immunobiology 2011; 216:882-890
23. Thurm CW, Halsey JF: Measurement of cytokine production using whole blood. Curr Protoc Immunol 2005; Chapter 7:Unit 7.18B
24. Clark JD, Gebhart GF, Gonder JC, et al: Special report: The 1996 guide for the care and use of laboratory animals. ILAR J 1997; 38:41-48
25. Myers MJ, Farrell DE, Palmer DC, et al: Inflammatory mediator production in swine following endotoxin challenge with or without co-administration of dexamethasone. Int Immunopharmacol 2003; 3:571-579
26. Boomer JS, To K, Chang KC, et al: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306:2594-2605
27. Oppert M, Schindler R, Husung C, et al: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005; 33:2457-2464
28. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids in the treatment of severe sepsis and septic shock in adults: A systematic review. JAMA 2009; 301:2362-2375
29. Moreno R, Sprung CL, Annane D, et al: Time course of organ failure in patients with septic shock treated with hydrocortisone: Results of the Corticus study. Intensive Care Med 2011; 37:1765-1772
30. Inamoto Y, Flowers ME: Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011; 18:414-420
31. Nguyen-Khac E, Thevenot T, Piquet MA, et al; AAH-NAC Study Group: Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365:1781-1789
32. Hirschfeld M, Ma Y, Weis JH, et al: Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165:618-622